हृदय विफलता में कार्डियोवास्कुलर-किडनी-मेटाबोलिक ओवरलैप, जिसमें ईजेक्शन फ्रैक्शन थोड़ा कम या संरक्षित होता है

Ostrominski et al. (Sun,) ने इस प्रश्न का अध्ययन किया।

www.synapsesocial.com/papers/69f41ba6ef2b80c36f936afb — DOI: https://doi.org/10.1016/j.jacc.2024.05.005

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017· 2020 · 6,422 citations
2. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021· 2024 · 2,338 citations
3. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction· 2008 · 1,933 citations
4. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association